Published by Josh White on 2nd October 2020
(Sharecast News) - Biopharmaceutical company Ovoca Bio updated shareholders on Friday on its marketing authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, that was submitted to the Russian Ministry of Health (Minzdrav) in September 2019.
URL: http://www.digitallook.com/dl/news/story/31255820/...